These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 2227773)
21. AIDS and FDA drug-approval policy: an evolving controversy. Gould SJ J Health Soc Policy; 1990; 2(2):39-46. PubMed ID: 10111761 [TBL] [Abstract][Full Text] [Related]
22. The FDA just says yes. MacPherson P Hosp Health Netw; 1996 May; 70(10):34-6, 38. PubMed ID: 8620201 [TBL] [Abstract][Full Text] [Related]
23. Investigational new drug regulations. AORN J; 1988 Jun; 47(6):1473. PubMed ID: 3389785 [No Abstract] [Full Text] [Related]
24. The fast track: federal agencies and the political demand for AIDS drugs. Foreman CH Brookings Rev; 1991; 9(2):30-7. PubMed ID: 10110828 [No Abstract] [Full Text] [Related]
25. US looking for short cuts to speed drug approval. Ezzell C Nature; 1988 Aug; 334(6183):553. PubMed ID: 3043232 [No Abstract] [Full Text] [Related]
26. Underground medicine. A quest for state-of-the-art treatments is turning thousands of ordinary Americans into activists--and sometimes outlaws. Lord M; Arrarte A; Dean J; Boram J US News World Rep; 1992 May; 112(18):62-71. PubMed ID: 10170976 [No Abstract] [Full Text] [Related]
27. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform. Rossen BR Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746 [TBL] [Abstract][Full Text] [Related]
29. AIDS drugs in development. Facts and comparisons. Hosp Pharm; 1993 Feb; 28(2):161, 165-7. PubMed ID: 10125704 [No Abstract] [Full Text] [Related]
30. Ethical problems arise over clinical trials on new drugs. Hosp Ethics; 1992; 8(5):12-3. PubMed ID: 10120132 [No Abstract] [Full Text] [Related]
31. Ethical implications of withdrawal of experimental drugs at the conclusion of phase III trials. Roginsky MS; Handley A Clin Res; 1978 Dec; 26(6):384-8. PubMed ID: 10239695 [No Abstract] [Full Text] [Related]
32. The case for patient access to experimental therapy. Delaney M J Infect Dis; 1989 Mar; 159(3):416-9. PubMed ID: 2915165 [No Abstract] [Full Text] [Related]
33. Investigational new drug regs: icing or cake? Margolis RE Healthspan; 1988 Dec; 5(11):25-6. PubMed ID: 10291398 [No Abstract] [Full Text] [Related]
34. Great expectations: is the U.S. doing its best to beat AIDS?. Interview by Don McLearn. Parkman PD FDA Consum; 1989 Feb; 23(1):36-8. PubMed ID: 10312853 [No Abstract] [Full Text] [Related]
35. Overhaul at the FDA begins. Science; 1992 Apr; 256(5055):313. PubMed ID: 1566081 [No Abstract] [Full Text] [Related]
36. New drug initiatives announced. Ann Pharmacother; 1992 Jun; 26(6):868. PubMed ID: 1611177 [No Abstract] [Full Text] [Related]
39. Controlled clinical trials of AIDS drugs: the best hope. Cooper EC JAMA; 1989 Apr; 261(16):2445. PubMed ID: 2649701 [No Abstract] [Full Text] [Related]